Cerebral Metastases: Translational Advances, Evaluation and Management
- 1st Edition, Volume 165 - June 25, 2025
- Editors: Paul B. Fisher, Paul B. Fisher, Mariza Daras, David Limbrick
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 3 4 5 9 1 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 4 5 9 2 - 0
Cerebral Metastases: Translational Advances, Evaluation and Management, Volume 165 in this ongoing series, highlights new advances in the field, with this new volume coveri… Read more
Cerebral Metastases: Translational Advances, Evaluation and Management, Volume 165 in this ongoing series, highlights new advances in the field, with this new volume covering many interesting topics, including Molecular Drivers in CNS metastasis, Role of the tumor microenvironment in CNS metastatic disease, Advanced Imaging to improve early diagnosis and evaluate treatment response, Liquid biopsy in early detection of CNS metastasis, Precision medicine approaches to CNS metastatic disease, IMRT/conventional RT, Single and hypofractionated SRS, Brachytherapy for recurrent metastases, LITT for treatment of active brain metastasis and radiation necrosis, and much more.
Other topics covered include Minimally-invasive surgical approaches in the management of brain metastases.
Other topics covered include Minimally-invasive surgical approaches in the management of brain metastases.
- Provides the latest information on cancer research and metastasis
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Provides invaluable information on the fast-moving field of cancer research that includes outstanding original reviews on a variety of topics
1. Molecular Drivers in CNS metastasis
Akanksha Sharma
2. Role of the tumor microenvironment in CNS metastatic disease
Adrienne Boire
3. Advanced Imaging to improve early diagnosis and evaluate treatment response
Javier E. Villanueva-Meyer
4. Liquid biopsy in early detection of CNS metastasis
Rachna Malani
5. Precision medicine approaches to CNS metastatic disease
Seema Nagpal
6. IMRT/conventional RT
Timothy Harris
7. Single and hypofractionated SRS
Jason P. Sheehan, Stylianos Pikis and Georgios Mantziaris
8. Brachytherapy for recurrent metastases
Steve Braunstein
9. LITT for treatment of active brain metastasis and radiation necrosis
Bill Broaddus, Theresa Gammel and Shawn D'Souza
10. Minimally-invasive surgical approaches in the management of brain metastases
Brian Nahed, Nicole Perez and Bryan Choi
Akanksha Sharma
2. Role of the tumor microenvironment in CNS metastatic disease
Adrienne Boire
3. Advanced Imaging to improve early diagnosis and evaluate treatment response
Javier E. Villanueva-Meyer
4. Liquid biopsy in early detection of CNS metastasis
Rachna Malani
5. Precision medicine approaches to CNS metastatic disease
Seema Nagpal
6. IMRT/conventional RT
Timothy Harris
7. Single and hypofractionated SRS
Jason P. Sheehan, Stylianos Pikis and Georgios Mantziaris
8. Brachytherapy for recurrent metastases
Steve Braunstein
9. LITT for treatment of active brain metastasis and radiation necrosis
Bill Broaddus, Theresa Gammel and Shawn D'Souza
10. Minimally-invasive surgical approaches in the management of brain metastases
Brian Nahed, Nicole Perez and Bryan Choi
- Edition: 1
- Volume: 165
- Published: June 25, 2025
- Language: English
PF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USAPF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USAMD
Mariza Daras
Dr. Mariza Daras is an Associate professor in the Department of Neurosurgery and the Chief of Neuro-oncology at Virginia Commonwealth University’s Massey Comprehensive Cancer Center in Richmond, Virginia. She began her academic medical career at Columbia College of Physicians and Surgeons, where she received her medical degree. After completing her Neurology residency at Duke University Medical Center and a Neuro-oncology fellowship at Memorial Sloan Kettering, she served as faculty in the Department of Neurology at Memorial Sloan Kettering. She subsequently took on a faculty position in the Division of Neuro-oncology at the University of California San Francisco where she spearheaded a CNS metastasis multidisciplinary program. In 2019, she joined VCU to lead the Division of Neuro-oncology. Dr. Daras has focused her research efforts on clinical trials for patients with primary and metastatic brain tumors, and specifically in the development of novel immunotherapeutic and combinatorial strategies. She has also dedicated her time to teaching and mentoring medical school students, residents, fellows, and advanced practice providers and is the Program Director of the VCU neuro-oncology fellowship. She is board-certified by the American Board of Psychiatry and Neurology and the United Council of Neurologic Subspecialties for neuro-oncology. Dr. Daras is a member of the American Academy of Neurology (AAN), Society for Neuro-Oncology (SNO), and American Society of Clinical Oncology (ASCO). She is an appointed member of AAN’s Committee on Public Engagement, as well as the AAN, Committee on Brain Health. She also serves as appointed member of the SNO Diversity and Women Committee, as well as the SNO/ASCO CNS Metastases Annual Conference.
Affiliations and expertise
Associate Professor, Department of Neurosurgery, Chief of Neuro-oncology, Virginia Commonwealth University’s Massey Comprehensive Cancer Center in Richmond, Virginia, USARead Cerebral Metastases: Translational Advances, Evaluation and Management on ScienceDirect